Monte Rosa Therapeutics
GLUE on Nasdaq. Biological products, (no diagnostic substances). Market value $876m.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
Nothing stands out yet.
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-3.81 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$9.87 a share, 36% above its 1-year low
Over the past year the price has ranged from $7.24 to $25.77.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | n/a | n/a | $0 | $76m | $124m |
| Operating margin | |||||
| Operating margin | n/a | n/a | n/a | -107.3% | -43.8% |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.05bn | 0.05bn | 0.06bn | 0.07bn | 0.09bn |
Health checks
- Free cash flow positive1 of 5 years
- Accounting checksSkipped: company is not yet profitable
- DebtUnknown
- Revenue growth, five yearsUnknown
- Buying back its own sharesNo, 76% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $9 million last quarter, down 61% on a year ago.
- A loss of $43 million, compared with a loss of $12 million a year ago.
- It loses 633 cents on each $1 of sales, after keeping 8 cents a year earlier.
- Over the past 12 months it spent $32 million more cash than it brought in. A year earlier it had $24 million spare.
- 23% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in 1 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $9m |
| December 2024 | $61m |
| March 2025 | $85m |
| June 2025 | $23m |
| September 2025 | $13m |
| December 2025 | $3m |
| March 2026 | $4m |
| June 2026 | $9m |
| Quarter to | Amount |
|---|---|
| September 2024 | -$24m |
| December 2024 | $13m |
| March 2025 | $47m |
| June 2025 | -$12m |
| September 2025 | -$27m |
| December 2025 | -$46m |
| March 2026 | -$45m |
| June 2026 | -$43m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 17 March 2026
- Next quarterly (estimated, 10-Q)
- 5 November 2026
Who owns it
None of the long-term investors we follow own it. 193 funds in all.
Largest holders overall
- Price T Rowe Associates$214mAdded
- NEA Management Company$186m
- BlackRock$166mAdded
- TCG Crossover Management$112m
- Vestal Point Capital, LP$111mAdded
- BVF$108m
- Baker Bros. Advisors LP$105m
- State Street$90mAdded
- Montanova Capital$86mCut
- Vanguard Capital Management$83mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
11 investors own more than 5%.
- T. Rowe Price Associates, Inc.Passive investor10.5%+3.0 ptsSince 30 June 2026
- Baker Bros. Advisors LPPassive investorat least 10.0%+3.3 pts(filed with 3 related holders)Since 31 March 2026
- Adam GoulburnPassive investorat least 8.1%−0.6 pts(filed with 8 related holders)Since 31 March 2026
- New Enterprise Associates 17, L.P.Passive investorat least 7.9%−1.8 pts(filed with 11 related holders)Since 1 July 2026
What they said
The information provided in Item 5(c) is hereby incorporated by reference. Depending on market conditions and other factors, NEA 17 and the Reporting Persons may dispose of additional shares of the Issuer.
Read the filing - BVF PARTNERS L P/ILPassive investorat least 6.3%+0.4 pts(filed with 9 related holders)Since 31 March 2026
- BlackRock, Inc.Passive investor6.3%Since 31 December 2024
- Chen YuPassive investorat least 5.5%−1.7 pts(filed with 4 related holders)Since 31 March 2026
- Vestal Point Capital, LPPassive investorat least 5.4%(filed with 1 related holder)Since 30 June 2026
- Montanova Capital, LLCPassive investorat least 4.2%−1.3 pts(filed with 2 related holders)Since 30 June 2026
- Versant Venture Capital VI, L.P.Passive investorat least 3.4%−1.7 pts(filed with 4 related holders)Since 7 January 2026
- FMR LLCPassive investorat least 2.8%(filed with 1 related holder)Since 30 May 2025
- The Vanguard GroupPassive investorSold down below 5%Since 30 September 2025
- Avoro Capital Advisors LLCPassive investorSold down below 5%Since 30 September 2025
| Holder | Stake | Since | |
|---|---|---|---|
T. Rowe Price Associates, Inc. Passive investor | 10.5%+3.0 pts | 30 June 2026 | |
Baker Bros. Advisors LP Passive investor | at least 10.0%+3.3 pts (filed with 3 related holders) | 31 March 2026 | |
Adam Goulburn Passive investor | at least 8.1%−0.6 pts (filed with 8 related holders) | 31 March 2026 | |
New Enterprise Associates 17, L.P. Passive investor | at least 7.9%−1.8 pts (filed with 11 related holders) | 1 July 2026 | What they saidThe information provided in Item 5(c) is hereby incorporated by reference. Depending on market conditions and other factors, NEA 17 and the Reporting Persons may dispose of additional shares of the Issuer. Read the filing |
BVF PARTNERS L P/IL Passive investor | at least 6.3%+0.4 pts (filed with 9 related holders) | 31 March 2026 | |
BlackRock, Inc. Passive investor | 6.3% | 31 December 2024 | |
Chen Yu Passive investor | at least 5.5%−1.7 pts (filed with 4 related holders) | 31 March 2026 | |
Vestal Point Capital, LP Passive investor | at least 5.4% (filed with 1 related holder) | 30 June 2026 | |
Montanova Capital, LLC Passive investor | at least 4.2%−1.3 pts (filed with 2 related holders) | 30 June 2026 | |
Versant Venture Capital VI, L.P. Passive investor | at least 3.4%−1.7 pts (filed with 4 related holders) | 7 January 2026 | |
FMR LLC Passive investor | at least 2.8% (filed with 1 related holder) | 30 May 2025 | |
The Vanguard Group Passive investor | Sold down below 5% | 30 September 2025 | |
Avoro Capital Advisors LLC Passive investor | Sold down below 5% | 30 September 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 8 sold $4m, $2m of it under preset trading plans.
- Bowen MatthewPrincipal Accounting OfficerSold
- Date
- 5 October 2026
- Shares
- 13
- Price
- $10.56
- Value
- $137
- Warmuth MarkusPresident & CEO, DirectorSold
- Date
- 16 July 2026
- Shares
- 9,500
- Price
- $23.18
- Value
- $220,219
- Champoux JenniferChief Operating OfficerSoldunder a preset trading plan
- Date
- 15 July 2026
- Shares
- 4,351
- Price
- $23.38
- Value
- $101,730
- Townson SharonChief Scientific OfficerSoldunder a preset trading plan
- Date
- 6 July 2026
- Shares
- 6,000
- Price
- $23.31
- Value
- $139,849
- Janku FilipChief Medical OfficerSoldunder a preset trading plan
- Date
- 30 June 2026
- Shares
- 5,407
- Price
- $24.50
- Value
- $132,472
- Janku FilipChief Medical OfficerSoldunder a preset trading plan
- Date
- 29 June 2026
- Shares
- 6,000
- Price
- $22.95
- Value
- $137,700
- Manning Anthony M.DirectorSold
- Date
- 29 June 2026
- Shares
- 10,000
- Price
- $23.11
- Value
- $231,100
- Janku FilipChief Medical OfficerSoldunder a preset trading plan
- Date
- 24 June 2026
- Shares
- 30,000
- Price
- $21.42
- Value
- $642,600
- Janku FilipChief Medical OfficerSoldunder a preset trading plan
- Date
- 23 June 2026
- Shares
- 11,845
- Price
- $20.22
- Value
- $239,506
- Townson SharonChief Scientific OfficerSoldunder a preset trading plan
- Date
- 23 June 2026
- Shares
- 3,000
- Price
- $20.00
- Value
- $60,000
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 5 October 2026 | Bowen Matthew Principal Accounting Officer | Sold | 13 | $10.56 | $137 |
| 16 July 2026 | Warmuth Markus President & CEO, Director | Sold | 9,500 | $23.18 | $220,219 |
| 15 July 2026 | Champoux Jennifer Chief Operating Officer | Sold under a preset trading plan | 4,351 | $23.38 | $101,730 |
| 6 July 2026 | Townson Sharon Chief Scientific Officer | Sold under a preset trading plan | 6,000 | $23.31 | $139,849 |
| 30 June 2026 | Janku Filip Chief Medical Officer | Sold under a preset trading plan | 5,407 | $24.50 | $132,472 |
| 29 June 2026 | Janku Filip Chief Medical Officer | Sold under a preset trading plan | 6,000 | $22.95 | $137,700 |
| 29 June 2026 | Manning Anthony M. Director | Sold | 10,000 | $23.11 | $231,100 |
| 24 June 2026 | Janku Filip Chief Medical Officer | Sold under a preset trading plan | 30,000 | $21.42 | $642,600 |
| 23 June 2026 | Janku Filip Chief Medical Officer | Sold under a preset trading plan | 11,845 | $20.22 | $239,506 |
| 23 June 2026 | Townson Sharon Chief Scientific Officer | Sold under a preset trading plan | 3,000 | $20.00 | $60,000 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 17 Mar 2026, plus the 10-Q filed 6 Aug 2026 and 5 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.